Aravive Biologics
Conducting clinical trials of its lead compound, batiraxcept (formerly AVB-500), in combination with standard anticancer treatments in multiple indications. Learn more
Launch date
Employees
Market cap
$3.0m
Enterprise valuation
($3m) (Public information from Feb 2024)
Share price
$0.0401 ARAV
Houston Texas (HQ)
Authorizing premium user...